Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has shared an announcement.
Alligator Bioscience has entered an evaluation and option agreement with an infectious disease company to explore its proprietary RUBY™ bispecific antibody format for infectious diseases. This agreement includes a two-year evaluation period and an exclusive option to negotiate a license, with an option fee of USD 75,000 payable to Alligator. This strategic move aims to leverage Alligator’s innovative antibody platforms to generate non-dilutive financing, supporting the company’s broader strategy while maintaining a focus on advancing its lead candidate, mitazalimab, into Phase 3 trials.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the tumor-specific immunosuppressive environment, offering potential benefits for cancer patients. The company’s lead drug candidate, mitazalimab, is advancing to Phase 3 development and has shown promising results in metastatic pancreatic cancer trials. Alligator Bioscience is listed on Nasdaq Stockholm and is based in Lund, Sweden.
Average Trading Volume: 464,993
Technical Sentiment Signal: Sell
Current Market Cap: SEK146.9M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.